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Abstract
Background: Hypoxia plays a relevant role in tumor-related inflammation toward the metastatic spread and cancer
aggressiveness. The pro-inflammatory cytokine interleukin-1β (IL-β) and its cognate receptor IL1R1 contribute to the
initiation and progression of breast cancer determining pro-tumorigenic inflammatory responses. The transcriptional
target of the hypoxia inducible factor-1α (HIF-1α) namely the G protein estrogen receptor (GPER) mediates a
feedforward loop coupling IL-1β induction by breast cancer-associated fibroblasts (CAFs) to IL1R1 expression by
breast cancer cells toward the regulation of target genes and relevant biological responses.
Methods: In order to ascertain the correlation of IL-β with HIF-1α and further hypoxia-related genes in triple-
negative breast cancer (TNBC) patients, a bioinformatics analysis was performed using the information provided by
The Invasive Breast Cancer Cohort of The Cancer Genome Atlas (TCGA) project and Molecular Taxonomy of Breast
Cancer International Consortium (METABRIC) datasets. Gene expression correlation, statistical analysis and gene set
enrichment analysis (GSEA) were carried out with R studio packages. Pathway enrichment analysis was evaluated
with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. TNBC cells and primary CAFs were used as
model system. The molecular mechanisms implicated in the regulation of IL-1β by hypoxia toward a metastatic
gene expression profile and invasive properties were assessed performing gene and protein expression studies, PCR
arrays, gene silencing and immunofluorescence analysis, co-immunoprecipitation and ChiP assays, ELISA, cell
spreading, invasion and spheroid formation.
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Results: We first determined that IL-1β expression correlates with the levels of HIF-1α as well as with a hypoxia-
related gene signature in TNBC patients. Next, we demonstrated that hypoxia triggers a functional liaison among
HIF-1α, GPER and the IL-1β/IL1R1 signaling toward a metastatic gene signature and a feed-forward loop of IL-1β
that leads to proliferative and invasive responses in TNBC cells. Furthermore, we found that the IL-1β released in
the conditioned medium of TNBC cells exposed to hypoxic conditions promotes an invasive phenotype of CAFs.
Conclusions: Our data shed new light on the role of hypoxia in the activation of the IL-1β/IL1R1 signaling, which
in turn triggers aggressive features in both TNBC cells and CAFs. Hence, our findings provide novel evidence
regarding the mechanisms through which the hypoxic tumor microenvironment may contribute to breast cancer
progression and suggest further targets useful in more comprehensive therapeutic strategies.
Keywords: Hypoxia, Hypoxia inducible factor-1α (HIF-1α), Interleukin-1β (IL-β), G protein estrogen receptor (GPER),
Breast cancer, Cancer-associated fibroblasts (CAFs)
Background
The triple-negative breast cancer (TNBC), which ac-
counts for 10–20% of all breast malignancies, is charac-
terized by the absence of the estrogen receptor (ER) and
the progesterone receptor (PR) without the amplification
of the human epidermal growth factor receptor 2
(HER2) [1]. TNBC displays a high heterogeneity, aggres-
sive features and poor overall survival rates [1–3]. Tar-
geted therapeutics for TNBC are currently limited and
the chemotherapy still remains the mainstay of treat-
ment, though the patients frequently develop resistance
[4]. Therefore, the identification of novel targeted ther-
apies is an imperative challenge to substantially improve
the outcome of the TNBC patients. In this context, hyp-
oxia and related effectors, as the hypoxia-inducible fac-
tors, have been suggested as important hallmarks of
TNBC [5, 6]. To date, hypoxia that represents one of the
most common conditions encountered within the breast
cancer microenvironment, has been associated with
tumor progression, increased risk of metastasis and mor-
tality [7]. Malignant cells may adapt to hypoxia mainly
through the action of the hypoxia-inducible factor-1α
(HIF-1α) [8], which has been largely involved in tumor
growth and vascularization, stromal cell recruitment,
extracellular matrix remodeling, premetastatic niche for-
mation, invasion and metastasis [7]. In this regard, it is
worth mentioning that an elevated expression of HIF-1α
has been associated with the aggressiveness of breast
cancer and poor clinical outcomes [9]. Likewise, the
over-expression of HIF-1α and the consequent hyperac-
tivation of its target genes have been indicated as key
drivers in the TNBC [10, 11].
Numerous transduction pathways, including the G
protein-coupled receptors (GPCRs), are engaged by the
hypoxia-mediated activation of the HIF-1α signaling
[12]. In this regard, our previous studies have demon-
strated that upon hypoxia and other stimulatory factors,
the G protein estrogen receptor, namely GPER, may
contribute to the action of HIF-1α toward breast tumor
growth and angiogenesis [13–17]. For instance, HIF-1α
was shown to be required for the up-regulation of GPER
by hypoxia and both HIF-1α and GPER triggered the
up-regulation of the vascular endothelial growth factor
(VEGF) in breast cancer cells and main components of
the tumor microenvironment, as cancer-associated fibro-
blasts (CAFs) [13].
The breast cancer microenvironment is characterized by
an intricate functional interplay among epithelial cancer
cells, the surrounding non-cancerous stromal cells (i.e.
CAFs, adipocytes, endothelial, mesenchymal, innate and
adaptive immune cells) and non-cellular components (i.e.
blood and lymphatic vessels, extracellular matrix compo-
nents) [18]. For instance, the bi-directional and intimate
communication of cancer cells with CAFs has been re-
ported to contribute to worse outcomes. In this vein, it is
well acknowledged that cancer cells through various fac-
tors educate fibroblasts toward their pro-tumorigenic
changes, which then characterize the stimulatory action of
CAFs [18–20]. Indeed, CAFs sustain the malignant prop-
erties of cancer cells synthesizing diverse extracellular
matrix components (ECM), cytokines and growth factors,
which in turn contribute to the metastatic cancer progres-
sion [21]. In this scenario, the dynamic network occurring
between cancer cells and CAFs relies on the production of
many effectors, as diverse chemokines exerting tumor-
promoting effects [22].
The interleukin-1 (IL-1) family consists of several ago-
nists, including IL-1α and IL-1β, and three receptor an-
tagonists including the specific receptor antagonist
IL1R1a [23]. The IL-1 receptor (IL-1R) family is instead
composed of more than 10 members, including the two
main receptors namely IL-1 receptor type I (IL1R1) and
the decoy receptor IL-1R type II [23]. As it concerns IL-
1β, its involvement in metastatic and angiogenic path-
ways toward breast cancer progression has been re-
ported [24, 25]. In this regard, our and other previous
studies have demonstrated that an estrogen-induced
feedforward loop couples the IL-1β induction in CAFs
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to the IL1R1-stimulatory action elicited in breast cancer
cells [26]. Likewise, high IL1β levels within the breast
tumor microenvironment have been associated with a
high tumor grade and an invasive cancer phenotype [27].
In the framework of the aforementioned data, here we
first show that a positive correlation between HIF-1α
and IL-1β expression occurs in large cohorts of TNBC
patients, as ascertained by querying public datasets.
Thereafter, we provide novel mechanistic evidence on
the hypoxia-prompted liaison between the HIF-1α/GPER
signaling and the IL-1β/IL1R1 axis, toward a metastatic
gene expression profile of TNBC cells and the engage-
ment of CAFs in facilitating invasive cancer features.
Methods
Publicly available molecular datasets
Gene expression analysis was performed using the publi-
cally available The Cancer Genome Atlas (TCGA) and
Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) datasets [28, 29]. Data was
downloaded on the 10 May 2020. The patients clinical
information along with the mRNA expression data
(RNA Seq V2 RSEM) reported in the Invasive Breast
Cancer Cohort of the TCGA project were downloaded
from UCSC Xena (https://xenabrowser.net/). The clin-
ical information and the microarray gene expression
data (Log2 transformed intensity values) of the METAB-
RIC cohort (n. 2509) were retrieved from cBioPortal for
Cancer Genomics (http://www.cbioportal.org/). Samples
of the TCGA cohort (n. 1247) were filtered by the “sam-
ple type” in order to obtain exclusively the tumor tissues
(n. 1101). Thereafter, patients of both TCGA and
METABRIC were classified on the basis of the presence
or the absence of the estrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor
receptor 2 (HER2), detected by immunohistochemistry.
Gene expression and clinical information were also fil-
tered for missing values. The final filtering resulted in
771 patients of TCGA and 1904 patients of METABRIC.
Correlation and pathway enrichment analysis
The Pearson correlation coefficients (r-values) between
the mRNA levels of HIF-1α and the other genes of the
TCGA (n. 20,530) dataset in TNBC cohort of patients
were assessed in R Studio (version 3.6.1) using the cor.t-
est() function and setting the method as “Pearson”. The
statistical analysis was performed by using the t-tests
considering significant the coefficients obtained with p <
0.001. The first 250 most correlated genes were selected
for the next evaluations. In particular, aiming to cluster
these genes in pathways, we uploaded our list on the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) functional annotation analysis web-
site (https://david.ncifcrf.gov/). We analyzed the genes
selecting the functional annotation tool and the option
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways, choosing the official gene symbol as “select
identifier” and gene list as “list type” in the options of
the upload and selecting a limit species of “Homo sapi-
ens” in the background.
Gene set enrichment analysis (GSEA)
Gene Set Enrichment Analysis (GSEA) was performed
using the gsea() function of the phenoTest package
(https://bioconductor.org/packages/release/bioc/html/
phenoTest.html) in R Studio. The KEGG “Cytokine-
cytokine receptor interaction” pathway (KEGG entry =
hsa04060) and “HIF-1 signaling” pathway (KEGG entry =
hsa04066) were selected as the reference gene sets. We
ranked the genes of the “Cytokine-cytokine receptor
interaction” pathway in accordance with the differential
expression within HIF-1α high and low (median expres-
sion value as threshold assessment) samples, and the
“HIF-1 signaling” pathway genes in accordance with the
differential expression within IL-1β high and low (me-
dian expression value as threshold assessment) samples.
Both analysis were performed only in the TNBC sub-
group of patients, verifying if the selected sets of genes
were enriched at the bottom or the top of the ranked
lists. We calculated the enrichment score (ES) that re-
flects the degree to which a set of genes is overrepre-
sented at the extremes (top or bottom) of the entire
ranked list. The score was calculated by walking down a
list of genes ranked by their correlation with the selected
phenotype (high or low HIF-1α/ IL-1β levels), increasing
a running-sum statistic when a gene in that gene set is
encountered (each vertical line underneath the enrich-
ment plot) and decreasing it when a gene that isn’t in
the gene set is encountered. The magnitude of the incre-
ment depends on the correlation of one gene with the
phenotype. In this analysis, 20,000 simulations were used
(B = 20,000). p < 0.05 was considered significant.
Reagents
The ROS scavenger N-acetyl-L-cysteine (NAC) (used at
a 300 μM concentration) and the proteasome inhibitor
MG132 (used at a 10 μM concentration) were purchased
from Merck Life Science (Milan, Italy). PD98059 (PD)
and LY294,002 (LY) (both used at a 1 μM concentration)
were obtained from Calbiochem (Milan, Italy). All com-
pounds were dissolved in DMSO, except NAC that was
solubilized in water. Recombinant human IL-1β (used at
a 10 ng/mL concentration) was purchased from Thermo
Fisher Scientific (Life Technologies Italia, Monza, Italy)
and solubilized in PBS with 1% BSA. The IL1R1 antag-
onist (IL1R1a) human recombinant protein (used at a
50 ng/mL concentration) was purchased from Thermo
Fisher Scientific and solubilized in 20 mM TBS, pH 8,
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with 50% glycerol. Anti-IL-1β neutralizing antibody
(MAB601) was purchased from R&D Systems (Bio-
Techne, Milano, Italy).
Cell cultures
The TNBC MDA-MB 231 breast cancer cells were pro-
vided by ATCC (Manassas, VA, USA), used less than 6
months after resuscitation, routinely tested and authenti-
cated according to the ATCC suggestions. MDA-MB
231 cells were maintained in DMEM/F12 (Dulbecco’s
modified Eagle’s medium) with phenol red, supple-
mented with 5% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (Thermo Fisher Scientific). CAFs
were isolated, cultured and characterized as previously
described [30] from 10 invasive mammary ductal carcin-
omas and pooled for the subsequent studies. Briefly,
specimens were cut into 1–2 mm diameter pieces, placed
in a digestion solution (400 IU collagenase, 100 IU hyal-
uronidase, 10% FBS, antibiotics and antimycotics)
(Thermo Fisher Scientific) and incubated overnight at
37 °C. Cells were then separated by differential centrifu-
gation at 90×g for 2 min. The supernatant containing fi-
broblasts were centrifuged at 485×g for 8 min, the pellet
obtained was suspended in fibroblasts growth medium
(Medium 199 and Ham’s F12 mixed 1:1 and supple-
mented with 10% FBS and 1% penicillin) (Thermo Fisher
Scientific) and cultured at 37 °C, 5% CO2. CAFs were
then expanded into 10-cm Petri dishes and stored as
cells passaged for three population doublings within
total 7 to 10 days after tis-sue dissociation. Primary cell
cultures of fibroblasts were characterized by immuno-
fluorescence with human anti-vimentin (V9; 1:500) and
human anti-cytokeratin 14 (LL001) (Santa Cruz Biotech-
nology, DBA, Milan, Italy; 1:250). FAPα antibody (H-56;
Santa Cruz Biotechnology, DBA, Milan, Italy; 1:500) was
used to assess fibroblast activation (data not shown). We
used CAFs passaged for up to 10 population doublings
for the experiments, to minimize clonal selection and
culture stress, which could occur during extended tissue
culture. All cell lines were grown in a 37 °C incubator
with 5% CO2 and switched to medium without serum
and phenol red the day before treatments to be proc-
essed for immunoblot and RT-PCR assays.
Gene expression studies and PCR arrays
Total RNA was extracted, and cDNA was synthesized by
reverse transcription as previously described [31]. The
expression of selected genes was quantified by real-time
PCR using platform Quant Studio7 Flex Real-Time PCR
System (Thermo Fisher Scientific). Gene-specific primers
were designed using Primer Express version 2.0 software
(Applied Biosystems) and are as follows: 5′-ACCT





(GPER forward) and 5′-GTGGGTCTTCCTCAGA
AGGG-3′ (GPER reverse); 5′-AGTCCCTGAGCATCTA
CGGT-3′ (COX2 forward) and 5′-CATCATCAGA
CCAGGCACCA-3′ (COX2 reverse); 5′-AAGCCACCCC
ACTTCTCTCTAA-3′ (ACTB forward) and 5′-CACC
TCCCCTGTGTGGACTT-3′ (ACTB reverse). Assays
were performed in triplicate and the results were nor-
malized for actin beta (ACTB) expression and then cal-
culated as fold induction of RNA expression.
PCR arrays were performed using a TaqMan™ Human
Tumor Metastasis Array (Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. The amplifi-
cation reaction and the results analysis were carried out
using platform Quant Studio7 Flex Real-Time PCR Sys-
tem (Thermo Fisher Scientific).
Gene silencing experiments and plasmids
Cells were transfected using X-treme GENE 9 DNA
Transfection Reagent (Roche Diagnostics, Merck Life
Science) for 24 h before treatments with a control vector
and a specific shRNA sequence or antisense vector for
each target gene. The short hairpin (sh) RNA constructs
to knock down the expression of HIF-1α and the control
shRNA construct were purchased form SABioscience
Corporation. Antisense vector for GPER (AsGPER),
which was generated by cloning of the entire open read-
ing frame of the receptor cDNA in the reverse orienta-
tion in pcDNA3.1 Hygro (−), was a kind gift from Eric R
Prossnitz (University of New Mexico Health Science
Center, Albuquerque, USA). The plasmid DN/c-fos,
which encodes for c-fos mutant that heterodimerizes
with c-fos dimerization partners but does not allow
DNA binding, was a kind gift from Dr. C. Vinson (NIH,
Bethesda, MD, USA).
Chromatin Immunoprecipitation (ChIP) assay
Cells were grown in 10-cm dishes, exposed to treat-
ments for 16 h, and then cross-linked with 1% formalde-
hyde and sonicated. Supernatants were immuno-cleared
with salmon DNA/protein A-agarose (Merck Life Sci-
ence) and immunoprecipitated with anti-HIF-1α or anti-
GPER antibody or nonspecific IgG. Pellets were washed,
eluted with a buffer consisting of 1%SDS and 0.1 mol/L
NaHCO3, and digested with proteinase K. DNA was ob-
tained by phenol/chloroform extractions and precipi-
tated with ethanol. The yield of target region DNA in
each sample after ChIP was analyzed by real-time PCR.
The primers used to amplify a region containing a HRE
site located into the GPER promoter sequence were: 5′-
TGCAGCACTTCAAAACAATAACC − 3′ (Fw) and 5′-
GGGTTTGAGTTGTTTTTCCTTTGG-3′ (Rv); the
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primers used to amplify a region containing a HRE site
located into the IL-1β promoter sequence were: 5′-
ACAGACAGGGAGGGCTATTG-3′ (Fw) and 5′-
GGGCAAGGAGTAGCAAACTA-3′ (Rv). Data were
normalized to the input for the immunoprecipitation
and the results were reported as fold changes respect to
nonspecific IgG.
Western blot analysis
Cells were grown in 10-cm dishes, exposed to treat-
ments, and then lysed as previously described [32]. Equal
amounts of whole-protein extract were resolved on a
10% SDS-polyacrylamide gel and transferred to a nitro-
cellulose membrane (Amersham Biosciences, Sigma-
Adrich, Milan, Italy), which were probed with primary
antibodies (1:1000) against HIF-1α and IL-1β (R&D Sys-
tems, Bio-Techne, Milano, Italy), GPER (AB137479)
(Abcam, DBA, Milan, Italy), phosphorylated ERK1/2 (E-
4), ERK2 (C-14), p-AKT1/2/3 (Ser 473)-R, AKT/1/2/3
(H-136), c-fos (E-8) and β-actin (AC-15; 1:4000) (Santa
Cruz Biotechnology, DBA, Milan, Italy) and then re-
vealed using the chemiluminescent substrate for western
blotting Westar Nova 2.0 (Cyanagen, Biogenerica, Cat-
ania, Italy). For nuclear extracts, cells were lysed using
300 μl of cytosolic buffer (50 mM HEPES pH 7.5, 150
mM NaCl, 1% Triton X-100, 1.5 mM MgCl2, 1 mM
EGTA, pH 7.5, 10% glycerol) with protease inhibitors
(1.7 mg/ml aprotinin, 1 mg/ml leupeptin, 200 mmol/liter
phenylmethylsulfonyl fluoride, 200 mmol/liter sodium
orthovanadate and 100 mmol/liter sodium fluoride). Fol-
lowing centrifugation (14,000 g, 4 °C, 10 min), the super-
natant was referred to as cytoplasmic fraction and the
pellet containing nuclei was resuspended in high salt
buffer (20 mM HEPES pH 7.9, 25% [v:v] glycerol, 420
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and protease
inhibitors). For the extraction of nuclear proteins, the
obtained solution was vortexed thoroughly, incubated
overnight with agitation and centrifugated at 14000 g,
4 °C for 10 min. Equal amounts of the collected super-
natant, which represent the nuclear fraction, were then
run on 10% SDS-PAGE and western blot analysis was
performed as described above. The purity of the nuclear
fraction was confirmed by immunoblotting with primary
antibodies against β-actin (AC-15; 1:4000) and anti-
LMNB/Lamin (M-20; 1:2000) (Santa Cruz Biotechnol-
ogy, DBA, Milan, Italy).
Co-immunoprecipitation assay
After exposure to treatments, cells were washed and
lysed using 500 μl RIPA buffer with protease inhibitors
(1.7 mg/ml aprotinin, 1 mg/ml leupeptin, 200 mmol/liter
phenylmethylsulfonyl fluoride, 200 mmol/liter sodium
orthovanadate and 100 mmol/liter sodium fluoride).
Samples were then centrifuged at 13,000 rpm for 10 min
and protein concentrations were determined using Coo-
massie (Bradford) protein assay. Proteins (200 μg) were
then incubated for 2 h with 900 μl of immunoprecipita-
tion buffer with inhibitors, 2 μg of anti-c-fos or anti-
GPER antibodies and 20 μl of Protein A/G agarose im-
munoprecipitation reagent (Santa Cruz Biotechnology,
DBA, Milan, Italy). Samples were then centrifuged at 13,
000 rpm for 5 min at 4 °C to pellet beads. Pellets were
washed four times with 500 μl of PBS and centrifuged at
13,000 rpm for 5 min at 4 °C. Supernatants were col-
lected, resuspended in 20 μl RIPA buffer with protease
inhibitors, 2X SDS sample buffer and heated to 95 °C for
5 min. Samples were then run on 10% SDS-PAGE, trans-
ferred to nitrocellulose and probed with primary anti-
bodies. Western blot analysis and ECL detection were
performed as described above.
Immunofluorescence microscopy
Cells were grown on a cover slip, serum deprived for 18
h and then exposed to treatments for 16 h. Next, cells
were fixed in 4% paraformaldehyde in PBS, perme-
abilized with 0.2% Triton X-100, washed 3 times with
PBS and incubated at 4 °C overnight with a primary anti-
body (1:250) against GPER (AB137479) (Abcam, DBA,
Milan, Italy) or Phospho-Myosin Light Chain 2 (Ser19)
(p-MLC) (Cell Signaling, Euroclone, Milan, Italy). After
incubation, the slides were extensively washed with PBS,
probed with alexa Fluor 594 goat anti-rabbit IgG (1:300,
Thermo Fisher Scientific) and 4′,6-diamidino-2-pheny-
lindole dihydrochloride (DAPI) (1:1000; Sigma-Aldrich).
Then, the images were obtained using the Cytation 3
Cell Imaging Multimode reader (BioTek, AHSI, Milan
Italy) and analyzed by the Gen5 software (BioTek, AHSI,
Milan Italy).
Phalloidin staining
Cells were exposed to treatments for 16 h, washed twice
with PBS, fixed in 4% paraformaldehyde in PBS for 10
min, washed briefly with PBS, then incubated with
Phalloidin-Fluorescent Conjugate (Santa Cruz Biotech-
nology). The images were obtained using the Cytation 3
Cell Imaging Multimode reader (BioTek, AHSI, Milan
Italy) and analyzed by the Gen5 software (BioTek, AHSI,
Milan Italy).
Enzyme-linked Immunosorbent assay
The concentrations of IL-1β in supernatants from
hypoxia-treated MDA-MB-231 cells were measured
using human IL-1β ELISA Kit (Thermo Scientific,
Monza Italy), according to the manufacturer’s instruc-
tions. The plates were read at 450 nm on a Microplate
Spectrophotometer Epoch™ (BioTek, AHSI, Milan Italy).
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Fig. 1 (See legend on next page.)
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DCFDA fluorescence measurement of ROS
The non-fluorescent 2′,7′-dichlorofluorescin diacetate
(DCFDA) probe was used to evaluate intracellular ROS
production. Briefly, cells were incubated with 10 μM
DCFDA (Sigma-Aldrich) at 37 °C for 30 min, washed
with PBS, and then exposed to treatments for 15 min, as
indicated. Cells were then washed with PBS, and the im-
ages were obtained using the Cytation 3 Cell Imaging
Multimode reader (BioTek, AHSI, Milan Italy) and ana-
lyzed by the Gen5 software (BioTek, AHSI, Milan Italy).
Conditioned medium
MDA-MB-231 cells were cultured under normal or low
oxygen tension (2%) for 16 h. Thereafter, the superna-
tants were collected, centrifuged at 3500 rpm for 5 min
to remove cell debris and used as conditioned medium
in the appropriate experiments.
Cell spreading assay
Cells were treated for 16 h, trypsinized and seeded onto
fibronectin (5 μg/ml) coated 96-well plate at a density of
2 × 105 cells/ml and incubated at 37 °C in a humidified
incubator containing 5% CO2. Phase-contrast images
were captured after 15 min and 60 min. As previously re-
ported [33], round bright cells were considered
unspread, whereas spread cells were defined as those
cells that had lost their phase-bright appearance and had
readily distinguishable nucleus and cytoplasm and quan-
tified by counting six randomly selected fields in each
well under a phase-contrast microscope.
Invasion assay
Transwell 8 μm polycarbonate membrane (Costar,
Sigma-Aldrich, Milan, Italy) was used to evaluate
in vitro cell invasion. 5 × 104 cells in 300 μL serum-free
medium were seeded in the upper chamber, coated with
Corning® Matrigel® Growth Factor Reduced (GFR) Base-
ment Membrane Matrix (Biogenerica, Catania, Italy) (di-
luted with serum-free medium at a ratio of 1:3). For
invasion assays in MDA-MB-231 cells, complete
medium was added to the bottom chambers in the pres-
ence of treatments where required, then cells were cul-
tured under normoxia or hypoxia for 16 h. For invasion
assays in CAFs, conditioned medium collected from
MDA-MB-231 cells previously exposed to hypoxia for
16 h was added to the bottom chambers in the presence
of treatments, where required. Cells on the upper sur-
face of the membrane were then removed by wiping
with Q-tip, and invaded cells were fixed with 100%
methanol, stained with Giemsa (Sigma-Aldrich, Milan,
Italy), photographed using Cytation 3 Cell Imaging
Multimode Reader (BioTek, AHSI, Milan Italy) and
counted using the WCIF ImageJ software.
Spheroid formation assay
For spheroid generation, 100 μL/well of MDA-MB 231
cell suspensions (1 × 104) were dispensed into 2% agar-
coated 24-well plates. Three days after seeding, tumor
spheroids (a single spheroid per well) were exposed to
treatments and a 50% medium and treatment replenish-
ment was performed every 2 days. Images were obtained
on day 20 using a conventional inverted microscope,
thereafter cell number per spheroid was determined by
trypsinizing three different spheroids, mixing the cell
suspension with trypan blue and counting the number
of viable cells. The total number of cells obtained was
divided by the number of trypsinized spheroids.
Statistical analysis
The statistical analysis was performed using ANOVA
followed by Newman-Keuls’ test to determine differ-
ences in means. The bioinformatics analyses, including
t-tests, box plots and scatter plots, were performed using
the R tidyverse package (https://www.tidyverse.org/pack-
ages/). p < 0.05 and p < 0.01 were considered statistically
significant.
Results
Expression levels of HIF-1α and IL-1β are correlated in
TNBC
It is well acknowledged that the transcription factor
HIF-1α acts as a molecular sensor within the hypoxic
breast tumor microenvironment toward aggressive can-
cer features [7]. Hence, we began our study evaluating
the gene signature associated with HIF-1α in TNBC pa-
tients that are characterized by a poor prognosis [34].
Exploring the TCGA cohort of TNBC patients, the 250
genes mostly correlated with HIF-1α were first ranked
(See figure on previous page.)
Fig. 1 a The “Cytokine-cytokine receptor interaction” signaling is a prominent transduction pathway associated with the expression of HIF-1α in
TNBC patients. The top 250 genes correlated with HIF-1α in the TCGA dataset were clustered using the KEGG pathway enrichment analysis. The
x-axis and the y-axis indicate respectively the −log10-adjusted p-value and the different KEGG pathways. The number of the genes represented in
the identified pathways is plotted on the right of each bar. The genes belonging to the “Cytokine-cytokine receptor interaction” pathway (listed
in the pink box) were ordered by their HIF-1α correlation coefficients (from high to low) (see Additional file 1). b GSEA confirms an enrichment of
the genes belonging to the “Cytokine-cytokine receptor interaction” pathway in the TNBC patients with high HIF-1α levels, as indicated. The
patients of the TCGA and METABRIC datasets were ranked in accordance with the differential HIF-1α expression levels. c GSEA reveals an
enrichment of the “HIF-1 signaling” genes in the TNBC patients with high IL-1β expression. Patients of the TCGA and METABRIC datasets were
ranked in accordance with the differential IL-1β expression levels. Enrichment scores (ES) and relative p-values are plotted
Lappano et al. Journal of Experimental & Clinical Cancer Research          (2020) 39:153 Page 7 of 22
by Pearson correlation coefficient. In order to investigate
the biological significance of these genes, KEGG pathway
analysis was then performed using DAVID. The top 250
HIF-1α correlated genes were enriched in a set of path-
ways, as schematically reported in Fig. 1a. The “Cyto-
kine-cytokine receptor interaction” transduction
pathway, including IL1B, IL1A, IL1R, IL6, IL6ST, IL7R,
IL1RAP, INHBA, OSMR and TGFBR2 that are strongly
associated with breast cancer progression [35–41], was
found significantly correlated with HIF-1α. Next, we per-
formed gene set enrichment analysis (GSEA) in order to
explore the “Cytokine-cytokine receptor interaction” ex-
pression profile according to the high and low HIF-1α
phenotypes of both TCGA and METABRIC cohorts of
TNBC patients. It is worth noting that the genes in-
cluded in the “Cytokine-cytokine receptor interaction”
pathway were found enriched in the group of patients
showing high HIF-1α levels (Fig. 1b). As IL-1β may con-
tribute to breast cancer development and metastasis [37]
and may regulate the migratory phenotype of TNBC
cells through HIF-1α [42, 43], we sought to evaluate
whether IL-1β could be involved in the activation of a
hypoxia-related gene signature in TNBC patients. In this
regard, we ascertained that the genes included in the
“HIF-1 signaling pathway” of the KEGG database are sig-
nificantly enriched in the TNBC cohorts displaying high
Fig. 2 a Scatter plots depicting the correlation between HIF-1α expression and IL-1β levels in TNBC patients of the TCGA and METABRIC cohorts.
The Pearson correlation coefficients (r) and the relative p-values are shown in each panel. b Box plots showing the differential IL-1β expression
levels in non-TNBC and TNBC patients, as found in the TCGA and METABRIC datasets. The number of patients and p-values are reported in
each panel
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IL-1β expression of both TCGA and METABRIC data-
sets (Fig. 1c). Further corroborating these observations, a
positive correlation between IL-1β and HIF-1α levels
was found in the TNBC cohorts of both databases
(Fig. 2a). Exploring the clinical significance of IL-1β in
TNBC patients, we assessed that the IL-1β expression
levels are significantly higher in TNBC compared to
non-TNBC in both TCGA and METABRIC datasets
(Fig. 2b). Overall, the aforementioned data suggests that
IL-1β is engaged by HIF-1α toward the development of
the aggressive TNBC.
GPER is involved in the up-regulation of IL-1β mediated
by HIF-1α upon hypoxia
On the basis of the aforementioned findings and in
order to provide novel insights on the regulation of IL-
1β by hypoxia in TNBC, we ascertained that a low oxy-
gen tension (2% O2, thereafter mentioned as hypoxia)
induces the mRNA (Fig. 3a) and protein (Fig. 3b) expres-
sion of IL-1β in MDA-MB-231 cells, which are a well-
recognized model system of TNBC. Upon hypoxic con-
ditions, the mRNA levels of HIF-1α did not display any
change (Fig. 3a) whereas an increased protein expression
Fig. 3 The HIF-1α/GPER signaling is involved in the expression of IL-1β induced by hypoxia. mRNA (a) and protein (b) expression of HIF-1α and
IL-1β evaluated respectively by real-time PCR and immunoblotting in MDA-MB-231 breast cancer cells cultured upon normoxia or hypoxia (2%
O2). In RNA experiments, values are normalized to the actin beta (ACTB) expression and shown as fold changes of mRNA expression induced by
hypoxia compared to normoxic cells. c IL-1β levels evaluated by ELISA in the supernatants collected from MDA-MB-231 cells cultured upon
normoxia or hypoxia. d The up-regulation of IL-1β observed in MDA-MB-231 cells cultured upon hypoxia is no longer evident silencing HIF-1α.
mRNA (e) and protein (f) expression of GPER evaluated in MDA-MB-231 cells cultured upon normoxia or hypoxia, as evaluated by real-time PCR
and immunoblotting, respectively. g Recruitment of HIF-1α to the HRE site located within the GPER promoter sequence in MDA-MB-231 cells
cultured upon hypoxia. In control samples nonspecific IgGs were used instead of the primary antibody. The amplified sequences were evaluated
by real-time PCR. h The up-regulation of GPER observed in MDA-MB-231 cells exposed to hypoxia was abrogated silencing HIF-1α. i Immunoblots
of HIF-1α and IL-1β from GPER-silenced MDA-MB-231 cells exposed to hypoxia. Side panels show densitometric analysis of the blots normalized
to β-actin. Values represent the mean ± SD of three independent experiments performed in triplicate. (*) and (○) indicate p < 0.05 for cells
cultured under normoxia versus cells cultured under hypoxia
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was observed (Fig. 3b), in accordance with the known
ability of hypoxia to decrease the HIF-1α ubiquitination
and degradation [9]. Next, performing ELISA assays we
determined that the secretion of IL-1β increases in the
medium of MDA-MB-231 cells cultured under hypoxia
(Fig. 3c). Remarkably, the silencing of HIF-1α abolished
the expression of IL-1β prompted by hypoxia, suggesting
that HIF-1α is involved in the up-regulation of IL-1β in
MDA-MB-231 cells exposed to hypoxic conditions. In
accordance with previous findings showing that HIF-1α
can be induced by proinflammatory stimuli including
IL-1β [43], we ascertained that IL-1β boosts the accumu-
lation of HIF-1α in MDA-MB-231 cells (Additional file 2).
Worthy, these results suggest that the HIF-1α-
dependent induction of IL-1β upon hypoxic conditions
may generate a feed-forward loop that further contrib-
utes to the stimulatory interaction between HIF-1α and
IL-1β signaling. Reminiscing our previous data on the
action of GPER in hypoxic conditions [13, 14], we
assessed that hypoxia triggers the up-regulation of GPER
mRNA (Fig. 3e) and protein (Fig. 3f) levels in a time-
dependent manner in MDA-MB-231 cells. By chromatin
immunoprecipitation (ChIP) assay, we then found that
HIF-1α is recruited to the GPER promoter region in
MDA-MB-231 cells exposed to hypoxia (Fig. 3g). More-
over, the silencing of HIF-1α prevented the protein in-
duction of GPER upon a 16 h exposure to hypoxic
conditions (Fig. 3h), indicating that HIF-1α is required
for the transcription of GPER in MDA-MB-231 cells ex-
posed to hypoxia. Next, the hypoxia increased HIF-1α
levels were not altered by the silencing of GPER that in-
stead abolished the induction of IL-1β (Fig. 3i). To-
gether, these findings suggest that upon hypoxia HIF-1α
is involved in the up-regulation of GPER, which then co-
operates with HIF-1α toward the regulation of IL-1β. In
order to evaluate the transduction mechanism mediating
the aforementioned responses, we first assessed that a
short exposure of MDA-MB-231 cells to hypoxia does
increase the levels of reactive oxygen species (ROS)
(Fig. 4a), which are required for the stabilization of HIF-
1α and the subsequent transduction of the hypoxia-
mediated signaling [44]. In the aforementioned experi-
mental condition, we next ascertained that the activation
of two main transduction regulators of HIF-1α, namely
ERK1/2 and Akt [45, 46], is prevented in the presence of
the ROS scavenger NAC (Fig. 4b). As c-fos expression is
a suitable molecular sensor of both GPER and HIF-1α
transduction signaling [14, 47, 48], we also determined
that the induction of c-fos protein levels observed upon
a 4 h exposure to hypoxia is no longer evident in the
presence of the MEK inhibitor PD, the PI3K inhibitor
LY (Fig. 4c) and NAC (Fig. 4d). Likewise, the increase of
HIF-1α, GPER and IL-1β protein levels upon a 16 h ex-
posure to hypoxia using either NAC (Fig. 4e) or PD and
LY (Fig. 4f), suggesting that the ROS activity triggers the
ERK1/2/Akt/c-fos transduction signaling toward the
hypoxic regulation of HIF-1α, GPER and IL-1β expres-
sion. In accordance with these findings, the transfection
in MDA-MB-231 cells of a plasmid encoding a mutant
of c-fos, namely dominant negative c-fos (DN/c-fos),
(See figure on previous page.)
Fig. 4 The ERK1/2 and AKT transduction pathways along with c-fos, HIF-1α and GPER are involved in the up-regulation of IL-1β induced by
hypoxia. a ROS generation in MDA-MB-231 cells cultured upon normoxia or 15 min hypoxia (2% O2) in the presence or absence of the free
radical scavenger NAC, as evaluated using the fluorescent probe DCF-DA. Scale bar 200 μM. Side panel shows the quantitative measurement of
intracellular ROS (DCF fluorescence obtained in normoxic cells was set as one-fold induction upon which ROS levels induced by hypoxia was
calculated). Values represent the mean ± SD of three independent experiments performed in triplicate. b The ERK1/2 and AKT activation induced
by 15 min hypoxia in MDA-MB-231 cells is no longer evident in the presence of NAC. Side panels show densitometric analysis of the blots
normalized to ERK2 and AKT that served as loading control, as indicated. c Immunoblot of c-fos from MDA-MB-231 cells cultured upon normoxia
or hypoxia and in the presence of MEK inhibitor PD98059 (PD) or PI3K inhibitor LY294,002 (LY). Immunoblots of c-fos (d), HIF-1α, GPER and IL-1β
(e) in MDA-MB-231 cells upon normoxia or hypoxia in the presence or absence of NAC. f Immunoblots of HIF-1α, GPER and IL-1β in MDA-MB-231
cells upon normoxia or hypoxia and in the presence of PD or LY. g Immunoblots of HIF-1α, GPER and IL-1β in MDA-MB-231 cells transfected with
a scramble or a dominant-negative c-fos construct (DN/c-fos) and thereafter exposed to normoxia or hypoxia. h The 26S proteasome inhibitor
MG132 rescued the HIF-1α repression observed in MDA-MB-231 cells transfected for 24 h with the DN/c-fos construct and exposed to low
oxygen tension (2%). Side panels show densitometric analysis of the blots normalized to β-actin. Values represent the mean ± SD of three
independent experiments performed in triplicate. i-j Co-immunoprecipitation assays performed in MDA-MB-231 cells cultured in normoxia or
hypoxia, as indicated. Cell lysates were immunoprecipitated with anti-c-fos (i) or anti-GPER (j) antibodies. Immunocomplexes were analyzed by
immunoblot with antibodies against the indicated proteins. In control samples, nonspecific IgG was used instead of the primary antibody. An
equal amount of the total lysates (input) was blotted for β-actin as loading control. k GPER expression evaluated by immunofluorescence assays
in MDA-MB-231 cells cultured upon normoxia or hypoxia. Nuclei were stained by DAPI (blue signal). Fluorescence intensities were quantified in
20 random fields for each condition and results are expressed as fold change of relative fluorescence units (RFU) over cells cultured upon
normoxia (set as one-fold induction). Enlarged details are shown in the separate box. l Immunoblots of nuclear fraction lysates derived from
MDA-MB-231 cells cultured upon normoxia or hypoxia. Side panel shows densitometric analysis of the blots normalized to laminin, which served
as a nuclear marker. β-actin served as a cytoplasmic marker. m Recruitment of HIF-1α and GPER to the HRE site located within the IL-1β promoter
sequence in MDA-MB-231 cells exposed to hypoxia. In control samples nonspecific IgG was used instead of the primary antibody. The amplified
sequences were evaluated by real-time PCR. Values represent the mean ± SD of three independent experiments performed in triplicate. (*), (○)
p < 0.05 for cells cultured upon normoxia versus cells cultured upon hypoxia
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abrogated the up-regulation of HIF-1α, GPER and IL-1β
triggered by a 16 h exposure to hypoxia (Fig. 4g). In
order to evaluate whether the reduction of HIF-1α pro-
tein levels triggered in the aforementioned experimental
condition by the DN/c-fos construct is associated with
the HIF-1α proteasome-dependent degradation, the
MDA-MB-231 cells were treated for 16 h with the prote-
asome inhibitor MG132. Notably, the MG132 rescued
the effects of the DN/c-fos construct on the HIF-1α pro-
tein levels (Fig. 4h), suggesting that c-fos is involved in
the complex HIF-1α biological regulation at the protea-
somal level. By co-immunoprecipitation studies, we also
found that hypoxia stimulates a direct interaction between
c-fos and HIF-1α in MDA-MB-231 cells (Fig. 4i), indicating
that the action of c-fos on HIF-1α stabilization at least in
part occurs through a physical interaction between these
two factors. Considering that in our previous study the func-
tional cooperation between HIF-1α and GPER triggered the
expression of certain genes in hypoxic conditions [13], we
first ascertained that HIF-1α co-immunoprecipitates with
GPER in MDA-MB-231 cells exposed to hypoxia (Fig. 4j).
Thereafter, we evidenced the accumulation of GPER in the
nuclear compartment of MDA-MB-231 cells exposed to
hypoxia, as evidenced by both immunofluorescence (Fig. 4k)
and subcellular fractionation studies (Fig. 4l). Intriguingly, by
ChIP assays we then demonstrated that the exposure to
hypoxia induces the recruitment of both HIF-1α and
GPER to a HRE site located within the IL-1β promoter se-
quence (Fig. 4m). Overall, these data suggest that a func-
tional interplay between HIF-1α and GPER may be
stimulated by hypoxia toward the transcription of IL-1β in
MDA-MB-231 cells.
Hypoxia triggers a functional cooperation among HIF-1α,
GPER and IL-1β/IL1R1 signaling toward a metastatic gene
expression profile and invasive properties of TNBC cells
In order to provide further insights into the metastatic
gene expression profile triggered by hypoxia through the
IL-1β/IL1R1 axis, we performed a TaqMan Gene Ex-
pression Assay, which consists of a Human Tumor Me-
tastasis Array. In this vein, MDA-MB-231 cells were
exposed for 16 h either to hypoxic conditions (Fig. 5a) or
the recombinant human IL-1β (Fig. 5b), in the presence
or absence of the IL1R1 antagonist IL1R1a. Considering
the genes resulting with at least a 0.25 log2 fold change
upon either hypoxia respect to normoxia-exposed cells
(Fig. 5a) or IL-1β respect to vehicle-treated cells (Fig.
5b), 31 and 15 metastatic genes induced respectively by
hypoxia and IL-1β were identified (Fig. 6a). Among the
11 genes up-regulated by either hypoxia or IL-1β as
depicted in the Venn diagram (Fig. 6a and Add-
itional file 3), we then focused on the regulation of IL-1β
and its target gene cyclooxygenase 2 (COX2) considering
that their strong increase was abrogated using the IL1R1
antagonist IL1R1a (Fig.5a-b). First, we ascertained that a
positive correlation does exist between IL-1β and COX2
levels in TNBC patients of the METABRIC dataset (Fig.
6b). Thereafter, we confirmed by real-time and western
blotting assays that the IL1R1 antagonist IL1R1a pre-
vents the mRNA (Fig. 6c) and protein (Fig. 6d-e) expres-
sion of both IL-1β and COX2 induced by a 16 h
exposure to either hypoxia or IL-1β treatment, in ac-
cordance with previous evidence demonstrating that IL-
1β may auto-regulate its own production [49]. Further-
more, we demonstrated that the COX2 protein induc-
tion by a 16 h hypoxic condition is prevented by
silencing GPER (Fig. 6f), indicating that GPER is in-
volved not only in the above described IL-1β expression
but also in the increase of COX2 upon hypoxia.
A hypoxic environment may lower cell-ECM adhesion
prompting cell motility and the epithelial to mesenchy-
mal transition toward aggressive breast cancer pheno-
types [50, 51]. Hence, we evaluated the contribution of
GPER and IL-1β/IL1R1 mediated signaling in the
metastasis-related responses induced by the hypoxia-
stimulated IL-1β action. In this regard, we assessed that
MDA-MB-231 cells cultured under hypoxic conditions
exhibit a reduced spreading ability on fibronectin 60 min
after seeding respect to cells grown under normoxic
conditions (Fig. 7a-b). Notably, this effect was no longer
evident silencing GPER as well as using the IL1R1 antag-
onist IL1R1a (Fig. 7a-b). Results similar to those men-
tioned above were observed treating cells with IL-1β
(Fig. 7c-d). Together, these findings suggest that both
GPER and IL-1β/IL1R axis contribute to hypoxia-
decreased cancer cell spreading on the ECM protein fi-
bronectin, according to previous data correlating the
hypoxia-lowered cell-ECM adhesion to an increased in-
vasion, intravasation and metastasis [52, 53]. Next, the
invasive effects prompted by both hypoxia and IL-1β
treatment were prevented not only by silencing GPER
but also using the IL1R1 antagonist IL1R1a, as evaluated
by Transwell Matrigel invasion assays (Fig. 7e-f). More-
over, both GPER silencing and IL1R1a lessened the
spheroid expansion upon hypoxia and IL-1β treatment
(Fig. 7g). Overall, these findings may suggest that the
(See figure on previous page.)
Fig. 5 Consistent expression changes of metastasis-related genes are induced by hypoxia and IL-1β in MDA-MB-231 cells, as evaluated by
TaqMan™ Human Tumor Metastasis Array. a MDA-MB-231 cells were cultured upon normoxia or hypoxia (2% O2) in the presence or absence of
the IL1R1 antagonist IL1R1a. b MDA-MB-231 cells were treated with vehicle or IL-1β alone or in combination with IL1R1a. Values were normalized
to the Glucuronidase Beta (GUSB) expression, the colors indicate the log2 fold changes of gene expression upon the indicated conditions
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signaling network of both HIF-1α/GPER and IL-1β/
IL1R, may lead to an auto-regulatory loop of IL-1β to-
ward invasive and metastatic properties of hypoxic
TNBC cells.
The hypoxic regulation of the IL-1β/IL1R1 signaling in
TNBC cells promotes an invasive CAFs phenotype
On the basis of the aforementioned findings, we sought
to provide mechanistic insights into the paracrine IL-1β
feedback on important components of the tumor micro-
environment as CAFs. In this vein, CAFs were cultured
with the conditioned medium (CM) collected from
MDA-MB-231 cells, which were exposed to hypoxia.
Interestingly, the up-regulation of both IL-1β and COX2
protein levels occurring in CAFs upon this experimental
condition (Fig. 8a) was prevented either using the IL1R1
antagonist IL1R1a (Fig. 8a) or the neutralizing IL-1β
antibody (Additional file 4). Findings similar to those
above mentioned were observed in CAFs treated with
IL1β (Fig. 8b). Considering that hypoxia may stimulate
breast cancer cells toward invasive features as cell motil-
ity, formation of stress fibers and matrix contraction
[54], the CM from MDA-MB-231 cells exposed to hyp-
oxia promoted in CAFs the phosphorylation of myosin
light chain (MLC) on serine-19 (pMLCS19) (Fig. 8c),
which is known to be required for the coordination of
the actin-myosin contractility [55]. In accordance with
these results, an increased MLC phosphorylation was ev-
idenced in CAFs treated with IL1β (Fig. 8d). Moreover,
immunofluorescent staining of polymerized actin (F-
actin) using FITC-conjugated phalloidin revealed an
augmented formation of stress fibers upon exposure of
CAFs to the CM from hypoxia-stimulated MDA-MB-
231 cells (Fig. 8e) as well as upon treatment with IL-1β
(Fig. 8d). Notable, both pMLCS19 phosphorylation and
the increased formation of actin stress fibers triggered in
CAFs by the CM from hypoxic MDA-MB-231 cells (Fig.
8c, e) and IL-1β treatment (Fig. 8d, f), were abolished in
the presence of the IL1R1 antagonist IL1R1a. Then, we
observed that the invasion of CAFs promoted by the
CM from hypoxia-exposed MDA-MB-231 cells (Fig. 8g)
or by IL-1β treatment (Fig. 8h), was no longer evident in
the presence of IL1R1a. Altogether, these results show
that the IL-1β production by the hypoxic TNBC cells
may trigger a paracrine feed-forward signaling that stim-
ulates malignant features in main components of the
breast tumor microenvironment as CAFs.
Discussion
In the current study we have provided novel insights re-
garding the hypoxia-mediated regulation of the IL-1β/
IL1R1 transduction signaling in TNBC cells and patient-
derived breast CAFs. First, we assessed that the genes
belonging to the “Cytokine-cytokine receptor inter-
action” pathway are both associated with HIF-1α expres-
sion in human TNBC samples and enriched in patients
showing high HIF-1α levels. Thereafter, we found that
the genes included in the “HIF-1 signaling pathway” are
enriched in the TNBC cohort displaying high levels of
IL-1β, which is a main component of the “Cytokine-
cytokine receptor interaction” pathway. Next, we ascer-
tained that IL-1β expression is higher in TNBC respect
to non-TNBC samples and correlates with HIF-1α in
TNBC patients. Mechanistically, we then assessed that
the HIF-1α/GPER transduction signaling is involved in
the hypoxia-regulated action of IL-1β, which triggers
both a metastatic gene signature and invasive features in
TNBC cells. Focusing on the functional interaction that
occurs between tumor cells and the surrounding stroma,
we also determined that IL-1β secreted by hypoxic
TNBC cells may promote a feed-forward loop engaging
its cognate receptor IL1R1 in breast CAFs. Corroborat-
ing these findings, we determined that the conditioned
medium collected from TNBC cells exposed to hypoxia
stimulates in CAFs the actin polymerization and the
MLC phosphorylation, which characterize the attain-
ment of invasive phenotypes.
Intratumoral hypoxia, which is a common feature in
solid cancers as breast cancer, is associated with an in-
creased risk of metastatic aggressiveness and patient
mortality [7]. Of note, cancer cells can adapt to low oxy-
gen tension activating the hypoxia-inducible factors that
mainly drive a peculiar gene expression signature [8]. As
well-known, the master regulators of the cellular
(See figure on previous page.)
Fig. 6 a Venn diagram of metastatic genes up-regulated in MDA-MB-231 cells in an exclusive and shared manner upon hypoxia (2% O2) and IL-
1β. The genes up-regulated by both hypoxia and IL-1β are listed in the box according to the gene expression changes induced by hypoxia (from
high to low) (see Additional file 3). b mRNA expression of IL-1β and COX2 in MDA-MB-231 cells cultured upon normoxia and hypoxia or vehicle
and IL-1β in the presence or absence of the IL1R1 antagonist IL1R1a, as evaluated by real-time PCR. Values are normalized to the actin beta
(ACTB) expression and shown as fold changes of the mRNA expression induced by hypoxia respect to normoxic cells. c Scatter plot depicting the
correlation between the expression of COX2 and IL-1β in TNBC patients of the METABRIC cohort of patients. The Pearson correlation coefficient
(r) and the relative p-value are indicated. d Immunoblots of IL-1β and COX2 in MDA-MB-231 cells cultured upon normoxia or hypoxia in
combination with IL1R1a, as indicated. e Immunoblots of IL-1β and COX2 in MDA-MB-231 cells treated with vehicle or IL-1β and in combination
with IL1R1a. f Immunoblots of COX2 in MDA-MB-231 cells upon normoxia and hypoxia silencing GPER. Side panels show densitometric analysis
of the blots normalized to β-actin. Values represent the mean ± SD of three independent experiments performed in triplicate. (*) p < 0.05 for cells
cultured under normoxia versus cells cultured under hypoxia or cells treated with IL-1β versus vehicle-treated cells
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adaptation to hypoxia consist of the oxygen-regulated
HIF-1α, HIF-2α and HIF-3α subunits and the constitu-
tively expressed HIF-1β subunit [8]. The HIF-1α, 2α and
3α subunits are subjected to oxygen-dependent pro-
cesses like prolyl hydroxylation, ubiquitination and pro-
teasomal degradation, which are inhibited upon hypoxia
that triggers the post-translational stabilization and the
HIF-α protein accumulation [9]. Subsequently, HIF-1α
binds to the hypoxia response elements regulating the
transcription of genes implicated in critical aspects of
cancer biology as angiogenesis, stem cell maintenance,
metabolic reprogramming, epithelial-mesenchymal tran-
sition, invasion, metastasis and resistance to therapy [9,
56, 57]. Likewise, hypoxia-activated HIF-1α plays a role
in the tumor-related inflammation leading to worse clin-
ical outcomes in diverse types of cancers including
breast tumors [58]. These events may occur through the
HIF-1α dependent regulation of signaling mediators and
inflammatory genes in both cancer and neighboring cells
within the tumor microenvironment [58]. Moreover, the
pro-tumorigenic action of HIF-1α may occur through its
interaction with various signaling pathways like trans-
forming growth factor-β, Wnt/β-catenin, Notch and
GPCRs [12, 59–61]. In this regard, GPER was shown to
be involved together with HIF-1α in the cell adaptation
to low oxygen tension in diverse tumors as breast cancer
[13, 14]. In particular, hypoxia-activated HIF-1α was
found to cooperate with GPER in breast cancer cells and
CAFs toward gene expression changes and relevant bio-
logical responses [13]. Intriguingly, GPER was also
shown to trigger the activation of the IL-1β/IL1R1 trans-
duction signaling, which in turn promoted inflammatory
responses and aggressive features of breast cancer cells
[26]. Further corroborating these findings, we here dem-
onstrate that a functional liaison between HIF-α and
GPER mediates the induction of IL-1β in TNBC cells ex-
posed to hypoxic conditions. In particular, we first evi-
denced that the up-regulation of GPER upon hypoxia
occurs through the recruitment of HIF-1α to a HRE site
located within the GPER promoter sequence in TNBC
cells. Then, we assessed that in hypoxic TNBC cells
HIF-1α and GPER are both recruited to the HRE site lo-
cated within the IL-1β promoter sequence. It is worth
mentioning that many studies have demonstrated that
GPER is detectable not only at the plasma membrane
level, but also in the intracellular and nuclear compart-
ments [13, 62–66]. As it concerns the signaling cascade
triggering the aforementioned findings, we demonstrated
that the ROS-dependent ERK1/2 and AKT activation to-
gether with the ensuing c-fos induction contribute to
the stabilization of HIF-1α as well as the up-regulation
of GPER and IL-1β in hypoxic TNBC cells. Co-
immunoprecipitation assays also revealed that c-fos both
interacts directly and protects HIF-1α from the protea-
somal degradation.
As largely reported, TNBC patients show an elevated
incidence of metastatic processes and low survival rates
[67, 68]. Unfortunately, TNBCs remain to be fully char-
acterized toward the assessment of reliable prognostic
markers and drug targets [69, 70]. Of note, “omics” tech-
nologies have recently provided intriguing insights into
the molecular landscape and the heterogeneous clinical
features of TNBC, leading to the identification of poten-
tially actionable targets [71, 72]. In this scenario, the
HIF-dependent signaling has been reported to be par-
ticularly active in TNBCs, suggesting that hypoxia may
play a relevant role toward the peculiar features of
TNBCs [5, 6]. Likewise, it has been ascertained that the
tumor-stroma inflammation network may prompt the
pro-metastatic phenotypes in TNBCs [73]. In this regard,
it should be mentioned that IL-1β acts as an important
effector of the oncogene-driven pathways linking inflam-
mation to cancer [74, 75]. Indeed, IL-1β is considered as
a master cytokine in the progression of breast cancer as
its production has been found correlated with advanced
diseases, whereas the IL1R1 inhibition by the antagonist
anakinra was shown to prevent the growth of breast can-
cer and the bone metastasis in mouse models [25, 37,
42, 76, 77]. Further corroborating these data, IL-1β was
found to contribute to the hypoxia-mediated angiogen-
esis through the up-regulation of HIF-1α [78]. In the
framework of these findings, we have here provided
(See figure on previous page.)
Fig. 7 The IL-1β/IL1R1 system is involved in the invasive and proliferative features induced by hypoxia in MDA-MB-231 cells. a-b Cell spreading
was evaluated in MDA-MB-231 cells transfected with scramble or AsGPER and exposed to normoxia or hypoxia (2% O2) in the presence or
absence of IL1R1a. Cells were then trypsinized, plated onto coverslips coated with fibronectin and the morphology was recorded after 15 min (a)
or 60 min (b). c-d Cell spreading was evaluated in MDA-MB-231 cells treated with vehicle and IL-1β alone or in combination with IL1R1a, as
indicated. Cells were then trypsinized, plated onto coverslips coated with fibronectin and the morphology was recorded after 15 min (c) or 60
min (d). Scale bar 50 μM. Side panels show quantification of cell spreading, as indicated. Data are representative of three independent
experiments performed in triplicate. e-f Transwell Matrigel invasion assay in MDA-MB-231 cells transfected with scramble or AsGPER and then
cultured in normoxia or hypoxia (e) or treated with vehicle or IL-1β (f) alone or in combination with IL1R1a, as indicated. Cells were counted in at
least 10 random fields in three independent experiments performed in triplicate, as quantified in the side panels. Scale bar 200 μM. g Spheroid
formation assay in MDA-MB-231 cells exposed to hypoxia and IL-1β alone or in combination with IL1R1a. Scale bar 100 μm. Side panel shows the
quantification of cell growth. Values represent the mean ± SD of three independent experiments performed in triplicate. (*), (○), (□) p < 0.05 for
cells cultured under normoxia versus cells cultured under hypoxia or treated with IL-1β versus vehicle-treated cells
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novel evidence regarding the hypoxic-induced IL-1β ex-
pression and function toward the metastasis-related gene
profile as well as the growth and invasive properties of
TNBC cells.
COX2 is the key enzyme in eicosanoid biosynthesis
and the master switch in the activation of the inflamma-
tory responses [79]. The induction of COX2 by inflam-
matory stimuli, including cytokines, triggers the
biosynthesis of prostaglandins from the arachidonic acid,
which is a 20-carbon polyunsaturated fatty acid released
from membrane phospholipids upon the phospholipase
A2 action [79]. Worthy, the constitutive expression of
COX2 and the sustained biosynthesis of the main ef-
fector of inflammation named prostaglandin E2 (PGE-2),
are both linked to mammary carcinogenesis due to their
stimulatory effects on mitogenesis, invasion and metasta-
sis, angiogenesis and immunosuppression [80–82]. In
addition, the overexpression of COX2 may occur in
approximately 50% of breast cancer and has been
found correlated with a reduced disease-free and
overall survival and the primary tumor size [83, 84].
Of note, in line with our findings regarding the
hypoxia-dependent activation of the IL-1β/COX2 sig-
naling toward the stimulation of growth and invasion
of TNBC cells, previous studies have shown that the
MDA-MB-231 cells display a lipidomic profile charac-
terized by high levels of polyunsaturated fatty acids
that are known to contribute to breast cancer pro-
gression, as mentioned above [85–87].
In the breast cancer microenvironment, the bidirec-
tional interplay occurring among neoplastic cells with
CAFs, tumor-associated macrophages, endothelial and
immune infiltrating cells, endorses tumor progression
stimulating responses as cell proliferation, invasion,
angiogenesis and metastasis [18, 19]. In particular, CAFs
may facilitate the establishment of a conducive microen-
vironmental niche for the cruitment and maintenance of
disseminated tumor initiating cells [88–90]. Likewise,
CAFs may regulate the malignant features fostering the
proliferative, migratory and invasive potential of sur-
rounding tumor cells [91]. In this respect, IL-1β was
involved in the connection between breast cancer cells
and mesenchymal stem cells (MSCs), which are consid-
ered an additional source of CAFs beyond the fibroblasts
[92, 93]. Worthy, the IL-1β-dictated cellular interaction
stimulated the production of diverse chemokines by
MSCs as well as an increased motility of TNBC cells
[93]. Nicely reminiscing these observations, we have here
demonstrated that hypoxic TNBC cells trigger IL-1β/
IL1R1 paracrine signals that prompt certain cytoskeletal
changes as the MLC-driven formation of actin stress fi-
bers toward invasive properties of breast CAFs. Overall,
our data provide novel evidence regarding the mecha-
nisms through which hypoxia triggers the IL-1β/IL1R1
signaling, which generates a feed-forward stimulatory
loop in both TNBC cells and CAFs. Our findings may be
therefore considered in more comprehensive therapeutic
strategies targeting breast cancer progression.
Conclusions
Our data provide novel evidence regarding the molecu-
lar mechanisms through which the IL1β-IL1R signaling
does prompt stimulatory effects upon hypoxia in TNBC
cells and CAFs. Considering the intricate interplay oc-
curring among diverse players activated by hypoxia even
through feed-forward loops, further efforts are warranted
to better appreciate this complex scenario toward more
comprehensive therapeutic strategies halting the aggres-
sive features of the TNBC.
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Additional file 1. The top 250 genes correlated with HIF-1α in the TCGA
dataset were clustered using the KEGG pathway enrichment analysis.
Additional file 2 Immunoblots of HIF-1α in MDA-MB-231 cells exposed
to IL-1β (10 ng/mL), as indicated. Side panel shows densitometric analysis
of the blot normalized to β-actin. Values represent the mean ± SD of
three independent experiments performed in triplicate. (*) p < 0.05.
Additional file 3. Pro-metastatic gene expression changes upon hyp-
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Fig. 8 The paracrine action of the IL-1β/IL1R1 axis promotes the actin-myosin contractility and the invasion of CAFs. a-b Immunoblots of IL-1β
and COX2 in CAFs exposed to conditioned medium (CM) collected from MDA-MB-231 cells cultured upon normoxia or hypoxia (2% O2) (a) and
in CAFs treated with vehicle or IL-1β (b), in the presence or absence of IL1R1a. c-d Phosphorylation of MLC in CAFs cultured with conditioned
medium (CM) collected from MDA-MB-231 cells exposed to normoxia and hypoxia (c) or IL-1β (d), in the presence or absence of the IL1R1
antagonist IL1R1a. Nuclei were stained by DAPI (blue signal). e-f CAFs exposed to conditioned medium (CM) from MDA-MB-231 cells grown
upon normoxia and hypoxia (e) or treated with IL-1β (f), in the presence or absence of the IL1R1 antagonist IL1R1a were stained with FITC-
phalloidin to detect F-actin stress fibers (green) and with DAPI to detect nuclei (blue). Fluorescence intensities of pMLC and the number of stress
fibers/cell was quantified based on F-actin staining in 20 random fields for each condition; results are expressed as fold change of relative
fluorescence units (RFU). Enlarged details are shown in the separate boxes. Scale bar 100 μM. g-h Transwell Matrigel invasion assay in CAFs
exposed to conditioned medium (CM) collected from MDA-MB-231 cells grown upon normoxia or hypoxia (g) or treated with IL-1β (h), in the
presence or absence of IL1R1a. Cells were counted in at least 10 random fields in three independent experiments performed in triplicate, as
quantified in side panels. Scale bar 200 μM. Values represent the mean ± SD of three independent experiments performed in triplicate. (*) p < 0.05
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induction of cells cultured respectively under normoxia or treated with
vehicle.
Additional file 4 Immunoblots of IL-1β and COX2 in CAFs exposed to
conditioned medium (CM) collected from MDA-MB-231 cells cultured
upon normoxia or hypoxia (2% O2), in the presence or absence of a neu-
tralizing IL-1β antibody (140 ng/mL). Side panel shows densitometric ana-
lysis of the blots normalized to β-actin. Values represent the mean ± SD
of three independent experiments performed in triplicate. (*) p < 0.05.
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